November 1, 1996Movement Disorders

Imaging of dopamine receptors with [¹²³I]iodobenzamide single‐photon emission–computed tomography in neuroleptic malignant syndrome

View Full Paper

Ask AI

Bookmark

Why the study?

Can [123I]iodobenzamide SPECT imaging monitor D2-receptor occupancy in a patient with neuroleptic malignant syndrome?

Structured PICO

Can [123I]iodobenzamide SPECT imaging monitor D2-receptor occupancy in a patient with neuroleptic malignant syndrome?

Population

1 patient (27-year-old man) with neuroleptic malignant syndrome (NMS) presenting with severe akinesia, rigor, tachycardia, fever, and elevated creatine phosphokinase level after neuroleptic medication

Intervention

[123I]iodobenzamide ([123I]-IBZM) single-photon emission-computed tomography (SPECT) imaging performed on days 6, 34, 90, 107, 131, and 201

Outcome

D2-receptor availability/occupancy in the acute phase and during the course of remissionsurrogate

IBZM-SPECT can successfully demonstrate D2-receptor occupancy in correlation with extrapyramidal signs in neuroleptic malignant syndrome.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Single-case IBZM-SPECT data suggest D2 monitoring feasibility in NMS; leaves open prospective validation before clinical use.

Cite This Study

Jauß et al. (1996) studied this question.

synapsesocial.com/papers/6a6f3118ac440176ef27e71f https://doi.org/10.1002/mds.870110621

View Full Paper

Ask AI

Bookmark

Imaging of dopamine receptors with [¹²³I]iodobenzamide single‐photon emission–computed tomography in neuroleptic malignant syndrome

Structured PICO

Discussion

Implication

Cite This Study

Imaging of dopamine receptors with [¹²³I]iodobenzamide single‐photon emission–computed tomography in neuroleptic malignant syndrome

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider